PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT Akers Biosciences, Inc.MyMD Pharmaceuticals, Inc. • March 31st, 2022 • In vitro & in vivo diagnostic substances • New York
THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on December 5, 2024 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Akers Biosciences, Inc., a New Jersey corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain engagement letter, by and between H.C. Wainwright & Co., LLC and the Company, dated as of September 6, 2019.
Fourth AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • March 31st, 2022 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This fourth AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of November 24, 2021 (the “Effective Date”), by and between Chris Chapman, M.D. (“Employee”) and MYMD Pharmaceuticals, Inc. (the “Company”), for the purpose of amending that certain Employment Agreement, dated as of November 1, 2020, and as amended on December 18, 2020, January 8, 2021, and February 10, 2021, by and between Employee and the Company (the “Agreement”). Terms used in this Amendment with initial capital letters that are not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.
Second AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • March 31st, 2022 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Second AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is entered into as of November 24, 2021 (the “Effective Date”), by and between Adam Kaplin, M.D. (“Employee”) and MYMD Pharmaceuticals, Inc. (the “Company”), for the purpose of amending that certain Employment Agreement, dated as of December 18, 2020, and as amended on February 10, 2021, by and between Employee and the Company (the “Agreement”). Terms used in this Amendment with initial capital letters that are not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.
